Androgen receptor antagonist 5 is used for the study of prostate cancer; it effectively inhibits the proliferation of prostate cancer LNCaP cells, impairs androgen receptor (AR) nuclear translocation, reduces nuclear AR levels, disrupts AR-mediated gene regulation, and exhibits antitumor activity in LNCaP xenograft mouse models.